A multicentric trial (Olympia-MITO 13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancer. by Fagotti A et al.
Research www.AJOG.org
ONCOLOGY
A multicentric trial (OlympiaeMITO 13) on the accuracy of
laparoscopy to assess peritoneal spread in ovarian cancer
Anna Fagotti, PhD; Giuseppe Vizzielli, MD; Pierandrea De Iaco, MD; Daniela Surico, MD; Alessandro Buda, MD;
Vincenzo Dario Mandato, PhD; Francesco Petruzzelli, MD; Fabio Ghezzi, MD; Salvatore Garzarelli, MD;
Liliana Mereu, MD; Riccardo Vigano`, MD; Saverio Tateo, MD; Francesco Fanfani, MD; Giovanni Scambia, MD
OBJECTIVE: The objective of the study was to prospectively evaluate RESULTS: One hundred sixty-eight cases were considered eligible for
the accuracy of laparoscopy performed in satellite centers (SCs) to
describe intraabdominal diffusion of advanced ovarian cancer
(AOC).
STUDY DESIGN: Patients with a clinical/radiological suspicion of AOC
were included in the protocol. SCs were selected among those sur-
geons, spending a short intensive training period at the coordinator
center (CC) to learn the application of staging laparoscopy (S-LPS) in
AOC. All women underwent S-LPS at the SCs, and the surgical pro-
cedure was recorded and blindly reviewed at the CC. Calculating
specificity, positive and negative predictive values, and the accuracy
for each parameter with respect to the CC assessed the diagnostic
performance of S-LPS. The Cohen’s kappa was used to test the
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462.e1 American Journal of Obstetrics& Gynecology NOVEMBER 2013the study. A per-protocol analysis was performed on 120 cases. The
worst laparoscopic assessable feature was mesenteric retraction,
whereas the remaining variables ranged from 99.2% (peritoneal
carcinomatosis) to 90% (bowel infiltration). All but 1 SC (SC number 4)
reached an accuracy rate of 80% or greater for both single parameters
and overall score. The Cohen’s kappa and the P value for overall
predicitive index value were 0.685 and .01, respectively, but improved
to 0.773 and .388 after removing the SC number 4 from the analysis.
CONCLUSION: S-LPS allows an accurate and reliable assessment of
intraperitoneal diffusion of disease in AOC patients in trained gyne-
cological oncology centers.
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cancer. Am J Obstet Gynecol 2013;209:462.e1-11.ost women with ovarian cancerM are diagnosed at an advanced
stage of disease, when large intraperito-
neal dissemination has already occurred.1
Nevertheless, maximal cytoreduction is
considered by several authors the best
option for cure to offer to these patients
because residual tumor (RT) after
primary surgery is one of the mostimportant prognostic factors in advan-
ced ovarian cancer (AOC).2,3
The number of womenwith AOCwho
undergo an optimal cytoreductive pro-
cedure widely varies in the literature,
depending on either surgeon’s training/
philosophy and patient’s characteristics.4
Therefore, a certain number of women
still undergo explorative laparotomySurgery, St. Maria Hospita
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therapy.5 To preoperatively identify
those patients able to achieve optimal
cytoreduction (RT less than 1 cm),4 thus
avoiding unnecessary laparotomies,
several approaches have been attempted,
including assessment of CA-125 serum
levels and computed tomography (CT)
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FIGURE 1
Flow diagram according to STARD statement
AOC, advanced ovarian cancer; LPS, laparoscopy; S-LPS, staging laparoscopy; STARD, Standards for the Reporting of Diagnostic
Accuracy Studies.
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www.AJOG.org Oncology Researchlevels do not always reflect tumor
burden, and CTscan has been unreliable
in predicting resectability of the disease.8
Moreover, the accuracy of these param-
eters has been limited by several factors,
such as the number of patients, retro-
spective nature of the studies, and the
highly different rates of optimal cytor-
eduction among the centers.9
In this context, we first demonstrated
that laparoscopy is able to provide the
same information as standard laparot-
omy regarding intraperitoneal diffusion
of AOC and consequently to accurately
assess the chances of optimal cytor-
eduction in these women.10 Thus, we
set up a laparoscopy-based quantitative
predictive model (predictive index value
[PIV]), which provides an objective
score related to intraabdominal disease
diffusion and predicts the likelihood of
optimal cytoreduction.11
As a subsequent step, we validated the
performance of this model in a larger
prospective cohort of AOC patients12
and tested its reliability in the gyneco-
logical oncology fellowship.13 Moreover,
the validation of the score in an external
center14 suggests that the laparoscopic
description of peritoneal cancer dis-
semination is feasible and objective.
Nevertheless, to definitively demonstrate
the reliability of a model, its prospective
application is needed in other centers
(satellite centers [SCs]) with different
surgical background with respect to the
one where it was developed (coordinator
center [CC]).
The prospective multicentric trial
Olympia-MITO 13 has been designed to
report the accuracy of laparoscopy to
describe intraabdominal diffusion of
AOC performed in different SCs with
respect to CCs in the same patient.
Indeed, the purpose of this study was to
verify the reproducibility of the scoring
system in the description of the tumor
spread rather than testing the ability of
the model to predict the likelihood of
optimal cytoreduction.
MATERIALS AND METHODS
Study design
Olympia-MITO 13 is a prospective mul-
ticentric trial registered (ClinicalTrials.
gov, no. NCT01595204). Each centerobtained the approval of the local ethical
committee before enrolling patients. The
design of the study is shown in Figure 1.
Women with first clinical and/
or radiological diagnosis of advanced
ovarian/fallopian tube or primary peri-
toneal cancer (International Federation of
Gynecology and Obstetrics stages III-IV)
were consecutively evaluated by a gyne-
cologic oncologist who proposed the trial.
Women accepting to be scheduled in the
study signed an informed consent to be
included in the protocol. Preoperative
evaluation of the patients consisted of a
complete physical and gynecological ex-
amination, assessment of CA-125 serum
levels, Eastern Cooperative Oncology
Group (ECOG) performance status, chest
X-ray, abdominopelvic CT scan, and
sonography.
Absolute exclusion criteria were rep-
resented by any clinical condition con-
traindicating laparoscopy (American
Society of Anesthesiologists [ASA] ofNOVEMBER 2013 Ameri3 or greater) and/or large masses occu-
pying the entire abdomen or infiltrating
the abdominal wall, not allowing a safe
and reliable laparoscopic evaluation. All
eligible patients were considered the
intention-to-treat population.
All SC surgeons were experienced
gynecologic oncologists in ovarian can-
cer management and laparoscopic sur-
gery. However, all SC surgeons took part
in a training course on ovarian cancer
management and radical surgery for at
least 2 months at the CC. The course
consisted of a direct participation to sur-
gery for advanced ovarian cancer with the
CC’s surgeons, comparison of laparo-
scopic and laparotomic features, and dis-
cussion of the patients’ clinical outcome.
These learning groups can add opportu-
nities to share experiences and learn from
each other, reducing the number of pro-
cedures for acquiring proficiency and
minimizing the disagreement in the
laparoscopic evaluation.13can Journal of Obstetrics& Gynecology 462.e2
FIGURE 2
Positive and negative evaluations of laparoscopic features (omental
cake, peritoneal carcinosis, diaphragmatic carcinosis, mesenteral
retraction) according to Fagotti’s scoring model
A1, Omental cake ¼ 2; A2, omental cake ¼ 0; B1, peritoneal carcinosis ¼ 2; B2, peritoneal carcinosis ¼ 0; C1, diaphragmatic
carcinosis ¼ 2; C2, diaphragmatic carcinosis ¼ 0; D1, mesenteral retraction ¼ 2; D2, diaphragmatic carcinosis ¼ 0.
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were submitted to staging laparoscopy
(S-LPS) at the SC, and the surgical pro-
cedure was performed according to
our previously published data.12 Video
registration of S-LPS was carried out at
the SC to assess the following parameters:
peritoneal and diaphragmatic carcino-
matosis, omental cake, mesenteral462.e3 American Journal of Obstetrics& Gynecolretraction, bowel and stomach infiltra-
tion, and superficial liver metastases.
The necessary characteristics required
to define a positive appraisal for each
laparoscopic features were previously
discussed, and each positive evaluation
received a score of 2.11 Specifically eval-
uations included the following: (1) peri-
toneal carcinomatosis, a score of 2 wasogy NOVEMBER 2013allotted only to the patients with massive
peritoneal involvement as well as with a
miliary pattern of distribution; on the
contrary, the score was 0 in the case of
carcinomatosis involving limited area (as
along the paracolic gutter or the pelvic
peritoneum) being surgically removable
by peritonectomy; (2) diaphragmatic
disease: a score of 2 was agreed in the case
of widespread infiltrating carcinomatosis
or confluent nodules to the utmost
part of the diaphragmatic surface; (3)
mesenteric disease: a score of 2 was
granted when large infiltrating nodules or
an involvement of the root of the mes-
entery were supposed on the basis of
limited movements of the various intes-
tinal segments. On the other hand, small
nodules potentially treated by ABC were
not considered for scoring; (4) omental
disease: a score of 2 was allotted when
tumor diffusion was observed along the
omentum up to the large stomach cur-
vature, whereas isolated localization were
excluded; (5) bowel infiltration: a score of
2 was agreed in the case that a bowel
resection was assumed or when extended
carcinomatosis on the ansae was ob-
served; (6) stomach infiltration: a score of
2was grantedwhen an obvious neoplastic
involvement of the gastric wall was
observed; and (7) liver metastases: a score
of 2 was allotted in the case of surface
lesions larger than 2 cm (Figures 2 and 3).
By summing the scores relative to all
parameters, a laparoscopic value for each
patient (total PIV) has been calculated.
Negative and inconclusive cases were
considered not evaluable because of the
poor quality of the video and the unex-
pected other malignancies at definitive
histology, respectively.
Positive cases consisted of evaluable
videos, which were blindly revised at the
CC, Division of Gynaecologic Oncology,
Catholic University of the Sacred Heart
in Rome, Italy, whose evaluation was
considered as the reference standard. In
fact, the correspondence between the
laparoscopic model and laparotomy-
verified parameters was demonstrated
by a previously published paper.10 At the
CC, a second blind laparoscopic assess-
ment of video for each parameter, and
overall PIV was performed and statistical
analysis elaborated.
FIGURE 3
Positive and negative evaluations of laparoscopic features (bowel
infiltration, stomach infiltration, superficial liver metastasis) according
to Fagotti’s scoring model
A1, bowel infiltration ¼ 2; A2, bowel infiltration ¼ 0; B1, stomach infiltration ¼ 2; B2, stomach infiltration ¼ 0; C1, superficial liver
metastasis ¼ 2; C2, superficila liver metastasis ¼ 0.
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eduction by S-LPS and the following
effective surgical management of these
patients were considered outside the
aim of the present study, but they will be
the objective of a future clinical trial.
Here the goal was to verify the accuracy
of the laparoscopic model in describing
intraabdominal diffusion of AOC in
different SCs, with respect to a CC. Any
correlation with CA-125 serum levels as
well as the abdominal CT scan assess-
ment were not analyzed. Any clinicaldecision about surgical management of
these women was outside the aim of the
study, and it was taken independently by
each SC.
Statistical analysis
Assuming the laparoscopic evaluation of
the CC as the gold standard to describe
the intraperitoneal tumor spread, we
tested the null hypothesis that the pos-
sibility of correctly identifying the peri-
toneal spread by the SC was not more
inferior than 80%. The cutoff of 80%NOVEMBER 2013 Ameriwas arbitrarily chosen because of the lack
of literature data and according to our
previously published papers (ie, the
overall accuracy of the model was
approximately 75%).11
This study was designed as a non-
inferiority trial and the sample size,
calculated according to Simon’s design,15
using an alpha error of 0.01 and a beta
error of 0.90, resulted in at least 75 cases,
as the whole population.
To avoid any bias related to the inex-
perience of the SC in treating AOC pa-
tients, it was planned a priori to perform
a per-protocol analysis only in those
centers enrolling at least 10 patients in
1 year.
The diagnostic performance of S-LPS
at the SC was assessed by calculating
specificity, positive and negative predic-
tive values (PPV and NPV, respectively),
and accuracy for each parameter with
respect to the CC. The Cohen’s kappa
was used to test the concordance
between SCs for each parameter.
Finally, the overall PIV was calculated
for each woman in the SC and tabulated
in the Bland-Altman plot.16 The median
PIV distribution in each SC was com-
pared with the CC median PIV by the
Cohen’s kappa test and accuracy.17
Significance was assumed at a P< .05.
Statistical calculations were performed
using the Statistical Package for Social
Sciences (version 17.0; SPSS Inc,
Chicago, IL).RESULTS
FromMarch 2010 toMarch 2012, 24 SCs
agreed to participate to the prospective
multicentric trial Olympia-MITO 13
(protocol identification NCT01595204).
Seventeen (70.8%) did actually enroll
patients. One hundred sixty-eight cases
with suspicious primary advanced
ovarian/peritoneal cancer were consid-
ered eligible for the study. Three women
(1.8%) refused S-LPS and were then
excluded. The remaining patients were
submitted to S-LPS at the SCs, and no
intraoperative complications were reg-
istered. Sixteen cases (9.5%) showed
poor quality of the video, whereas 4 cases
(2.4%) resulted in other malignancies at
definitive pathological findings. Onecan Journal of Obstetrics& Gynecology 462.e4
TABLE 1
Patient characteristics
Parameter n (%)
Eligible cases 168
Evaluable casesa 145 (86.3)
Member centers 24
Enrolling centers 17 (70.8)
Evaluable centersb 10 (58.8)
Median age (y) (range) 62 (32e92)
Median ECOG PS (range) 1 (0e2)
Histologyc
Type I 12 (8.2)
Type II 133 (91.8)
Stage
IIIC 113 (77.9)
IV 32 (22.1)
ECOG, Eastern Cooperative Oncology Group; PS, per-
formance status.
a Not included for refusing staging laparoscopy, poor
quality of video, or other malignancies; b Center
enrolling at least 10 cases/year; c According to
Kurman and Shih.18
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Research Oncology www.AJOG.orghundred forty-five patients (86.3%)
were evaluable at the CC (Table 1).
A per-protocol analysis was per-
formed on 120 cases. As shown in
Table 2, the worst assessable feature was
mesenteric retraction, which was not
evaluated in 31 of 120 cases (25.8%). The
remaining variables were quite homo-
geneously valuable, ranging from 99.2%
(peritoneal carcinomatosis) to 90%
(bowel infiltration). The main obstacles
that prevented the SCs from assessing
the laparoscopic features were the pres-
ence of tumor adhesions and diffused
carcinomatosis or the absence for pre-
vious surgery, such as for omentum. The
interrate agreement between SCs and
the CC was calculated by Cohen’s kappa
for each parameter and ranged from 0.63
(stomach infiltration) to 0.87 (omental
involvement).
The PPV and NPV and accuracy rate
for each parameter and for overall PIV
were then calculated in every SC. All but
1 SC reached an accuracy rate of 80% or
greater for both single parameters and
overall PIV. The overestimation of peri-
toneal and diaphragmatic carcinoma-
tosis resulted in a very low PPV (18.2%
and 66.7%, respectively) in the SC
number 4, thus negatively influencing
the previously defined cutoff accuracy of
80% or greater for each variable (peri-
toneal and diaphragmatic carcinoma-
tosis, 35.7% and 78.7%, respectively)
and for overall PIV (50%) (Figure 4 and
Appendix; Supplementary Table). The
interrate agreement (Cohen’s kappa)TABLE 2
Accuracy of laparoscopic assessmen
Parameter
Not evaluable,
n (%)
Omental cake 3 (2.5)
Peritoneal carcinomatosis 1 (0.8)
Diaphragmatic carcinomatosis 2 (1.6)
Mesenteral retraction 31 (25.8)
Bowel infiltration 12 (10.0)
Stomach infiltration 8 (6.6)
Superficial liver metastasis 4 (3.3)
NPV, negative predictive value; PPV, positive predictive value.
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462.e5 American Journal of Obstetrics& Gynecoland the P value for the overall PIV were
0.685 and .01, respectively, but improved
to Cohen’s kappa ¼ 0.773 and P ¼ .388
after removing the SC number 4 from
the analysis (Table 3).
Overall PIV was superimposable in 59
of 120 patients (49.2%), and 114 cases
(95%) ranged within 95% confidence
interval (CI) (Figure 5). Regarding 6
patients not included within 95% CI, 4
(3.3%) received an underestimation and
2 (1.6%) an overestimation of the
diffusion of the disease.
COMMENT
In the light of some recent advances in
ovarian cancer treatment,19-21 the cor-
rect timing to perform debulking sur-
gery is a crucial point in the natural
history of the disease.
In this context, the availability of a
minimally invasive approach, such
as S-LPS, able to directly visualize
intraperitoneal cavity as the preferred
site of ovarian cancer diffusion, is a
great diagnostic opportunity for the
surgeon to draw a more individualized
management of AOC. However, the
introduction of a laparoscopic assess-
ment to predict optimal cytoreduc-
tion in AOC into clinical practice
may be biased by other subjective
tools, such as patients’ and surgeon’s
characteristics.
In our opinion, although such a
dilemma can be ascribed to many other
predictive tools, as, for example, CA-125
serum levels or CT scan, the intrinsict for each parameter (per-protocol ana
False positive,
n (%)
False negative,
n (%) NPV, % PPV, %
5 (4.2) 2 (1.7) 95.8 92.8
15 (12.6) 1(0.8) 97.9 78.9
8 (6.7) 3 (2.5) 92.9 89.6
4 (4.4) 4 (4.4) 94.0 82.6
8 (7.4) 11(10.1) 81.7 83.3
4 (3.5) 3 (2.6) 97.0 63.6
5 (4.3) 4 (3.4) 95.7 78.3
rian cancer. Am J Obstet Gynecol 2013.
ogy NOVEMBER 2013value of any objective evaluation still
remains undoubted. In addition to its
safety in terms of complications and
survival, the reproducibility of the
technique seems the most important
challenge to the large diffusion of this
approach.12,22 The present study offers
the scientific bases to definitivelylysis)
Specificity, %
Accuracy,
n (%) Cohen’s kappa
90.2 110 (94.0) 0.878
75.8 103 (86.5) 0.733
83.0 107 (90.7) 0.802
94.0 81 (91.0) 0.766
86.0 89 (82.4) 0.646
96.1 105 (93.7) 0.632
94.7 107 (92.2) 0.752
FIGURE 4
Accuracy of each parameter and PIV in the SCs
The evaluation of each laparoscopic parameter and PIV is represented by a decagon. The vertices of
the decagons (from 1 to 10) correspond to the SCs. The percentages of accuracy (from 0 to 100) are
indicated on the axes for each SCs. The black boxes express the accuracy achieved by SCs.
PIV, predictive index value; SC, satellite center.
Fagotti. Diagnostic accuracy of laparoscopy in advanced ovarian cancer. Am J Obstet Gynecol 2013.
www.AJOG.org Oncology Researchrecommend S-LPS as a valid diagnostic
tool in the algorithm of treatment of
advanced ovarian cancer patients. InTABLE 3
Accuracy of PIV in the satellite cente
Variable
Satellit
median
Center 1 8 (0e1
Center 2 5 (0e1
Center 3 2 (0e1
Center 4 6 (0e8
Center 5 8 (2e1
Center 6 7 (0e12
Center 7 5 (0e10
Center 8 8 (2e12
Center 9 2 (0e12
Center 10 2 (0e8)
Overall centers 6 (0e14
Overall centers removing center 4 6 (0e14
PIV, predictive index value.
Fagotti. Diagnostic accuracy of laparoscopy in advanced ovaparticular, it shows that, following some
simple rules, as previously defined,11
many centers are able to correctlyrs
e center,
PIV (range)
Coordinator center,
median PIV (range) P valu
2) 8 (0e12) .713
4) 5 (0e8) .739
2) 2 (0e14) .898
) 2 (0e8) .039
4) 8 (2e14) .650
) 6 (0e14) .514
) 4 (0e8) .319
) 6 (2e12) .545
) 3 (0e12) .853
3 (0e8) .529
) 4 (0e14) .01
) 6 (0e14) .388
rian cancer. Am J Obstet Gynecol 2013.
NOVEMBER 2013 Ameridescribe AOC intraperitoneal diffu-
sion by S-LPS instead of standard
laparotomy.
The specificity of each laparoscopic
feature in all centers ranged between
75.8% (peritoneal carcinomatosis) and
96.1% (stomach infiltration), with the
highest accuracy rate for omental cake
(94.0%) and the lowest for bowel infil-
tration (82.4%). The quite disappointing
low performance of peritoneal carcino-
matosis may be influenced by the highest
rate of false-positive cases, which
reached 12.6%. From a clinical point of
view, it means that women with few
peritoneal nodules were considered
positive at the SCs and negative at the
CC, thus disregarding the definition of
peritoneal carcinomatosis previously
stated for the laparoscopic model.11
It is conceivable that such error can be
easily corrected through a larger sharing
of the laparoscopic criteria and/or a
longer training of some SCs’ surgeons in
a specific fellowship program on both
laparoscopy and oncologic surgery,
based on published data.13 This is the
case of SC number 4, which failed to
reach the previously defined cutoff
accuracy of 80% or greater, for both
peritoneal and diaphragmatic car-
cinomatosis. Nevertheless, the fulle Cohen’ s kappa Accuracy, %
0.865 93.3
1.00 100.0
1.00 90.9
0.169 50.0
1.00 100.0
0.833 91.6
0.636 83.3
0.847 92.3
1.00 100.0
0.615 90.0
0.685 84.1
0.773 88.6
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FIGURE 5
Comparison between PIV in the SCs vs CC (Bland-Altman’s plot)
The Bland-Altman’s plot shows a scatter diagram of the differences plotted against the averages of
the 2 measurements (SCs and CC’s PIV). Horizontal lines are drawn at the mean difference and at the
limits of agreement, which are defined as the mean difference 1.96 times the standard deviation
of the differences. In brackets, the number of cases for each scatter dot is reported.
CC, coordinator center; PIV, predictive index value; SC, satellite center.
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model cannot ignore the theoretical and
clinical background in gynecologic
oncology, in which S-LPS finds its
maximal application. For instance, in
our institution, we have learned over
time that the presence of carcinomatosis
over the anterior diaphragm surface is
often associated with the presence of
tumor along the posterior declivous
areas, whose removal would require
extensive peritonectomy or even dia-
phragmatic resection. Moreover,
although the evaluation of each laparo-
scopic feature is interesting, its assess-
ment was not chosen on the basis of a
direct correlation with the chances of
optimal cytoreduction but rather to fully
describe the intraabdominal diffusion of
the disease. Thus, in no case should they
be deemed as indices of inoperability by
themselves: only the combination of
them, expressed by the PIV, could be
considered as an indirect sign of the
biological aggressiveness of the tumor.
As expected, the median PIV elabo-
rated in each SC showed no statistically
significant difference with respect to the
median PIV in the CC, except for SC
number 4. Therefore, removing SC
number 4 from the statistical analysis,
the model achieves an accuracy rate of
88.6% with a P ¼ .388. In our opinion,
the identification of the error, in terms
of both technical evaluation and SC,
makes the model even more appealing,
thanks to its ability to self-correct.
Moreover, the removal of the failing SC
represents a merely statistical artifact,
switching the accuracy from 84.1% to
88.6% without changing the clinical
impact of the study.
Indeed, about half of the patients
showed a superimposable PIV between
the SCs and the CC, with 95% of the
cases lying within 95% CI. Regarding 6
women not included within 95% CI,
only 2 (1.6%) received an overestimated
score, hindering any possible optimal
cytoreduction. However, considering
that this value can be improved through
an intensive training program,13 it ap-
pears an excellent result so far.
Moreover, the issue of higher costs for
S-LPS with respect to other standard
diagnostic procedures such as CT scan462.e7 American Journal of Obstetrics& Gynecolor magnetic resonance imaging is
questionable. In fact, because the his-
tological diagnosis and surgical staging
are mandatory in advanced ovarian
cancer patients, S-LPS should be
considered as the first surgical step to
which these cases are submitted. In fact,
the chance for the surgeon to move
immediately toward maximal cytor-
eduction if the case is feasible greatly
decreases the costs. Moreover, consid-
ering the nonnegligible rate of false-
positives/negative values obtained with
standard diagnostic procedures and the
fast recovery of the patients after S-LPS to
promptly start chemotherapy, it appears
a good compromise between no surgical
exploration and longitudinal exploratory
laparotomy in advanced cases.
In conclusion, the routine use of S-LPS
allows an objective assessment of intra-
peritoneal diffusion of disease in primary
AOC patients. It has the potential to
properly select high-risk cases forogy NOVEMBER 2013suboptimal debulking, related to the
extension of disease. Such women can be
referred to high-volume hospital with
surgeons dedicated to extensive cytor-
eduction or they may be submitted to
neoadjuvant chemotherapy. In addition,
the correct description of anatomic
spread, extent, and size of the tumor may
be useful for designing future clinical
trials.22 -REFERENCES
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Accuracy of each laparoscopic parameter in each SC
Variable Assessable, % Specificity, % NPV, % PPV, % Accuracy, %
Center 1
Omental cake 100.0 80.0 66.7 88.9 80.0
Peritoneal carcinomatosis 100.0 83.3 100.0 90.0 93.3
Diaphragmatic carcinomatosis 100.0 100.0 100.0 100.0 100.0
Mesenteral retraction 93.3 87.5 87.5 83.3 85.7
Bowel infiltration 86.6 80.0 66.7 85.7 76.9
Stomach infiltration 93.3 92.3 100.0 50.0 92.8
Superficial liver metastasis 93.3 80.0 100.0 66.7 85.7
Center 2
Omental cake 100.0 100.0 100.0 100.0 100.0
Peritoneal carcinomatosis 100.0 100.0 100.0 100.0 100.0
Diaphragmatic carcinomatosis 100.0 83.3 100.0 80.0 90.0
Mesenteral retraction 90.0 85.7 85.7 50.0 77.8
Bowel infiltration 100.0 100.0 83.3 100 90.0
Stomach infiltration 100.0 90.0 100.0 n.a. 90.0
Superficial liver metastasis 100.0 80.0 100.0 n.a. 80.0
Center 3
Omental cake 90.9 100.0 100.0 100.0 100.0
Peritoneal carcinomatosis 100.0 85.7 100.0 80.0 90.9
Diaphragmatic carcinomatosis 100.0 85.7 100.0 80.0 90.9
Mesenteral retraction 81.8 100.0 100.0 100.0 100.0
Bowel infiltration 100.0 100.0 100.0 100.0 100.0
Stomach infiltration 100.0 90.0 100.0 50.0 90.9
Superficial liver metastasis 100.0 100.0 90.9 n.a. 90.9
Center 4
Omental cake 100.0 85.7 100.0 87.5 92.8
Peritoneal carcinomatosis 100.0 25.0 100.0 18.2 35.7
Diaphragmatic carcinomatosis 100.0 62.5 100.0 66.7 78.5
Mesenteral retraction 78.5 100.0 n.a. n.a. 100.0
Bowel infiltration 92.8 90.9 90.9 50.0 84.6
Stomach infiltration 100.0 100.0 92.8 n.a. 92.8
Superficial liver metastasis 100.0 100.0 100.0 n.a. 100.0
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SUPPLEMENTARY TABLE
Accuracy of each laparoscopic parameter in each SC (continued)
Variable Assessable, % Specificity, % NPV, % PPV, % Accuracy, %
Center 5
Omental cake 100.0 100.0 100.0 100.0 100.0
Peritoneal carcinomatosis 100.0 33.3 100.0 83.3 84.6
Diaphragmatic carcinomatosis 100.0 100.0 100.0 100.0 100.0
Mesenteral retraction 69.2 100.0 83.3 100.0 88.8
Bowel infiltration 92.3 100.0 75.0 100.0 84.6
Stomach infiltration 92.3 90.0 100.0 66.7 91.6
Superficial liver metastasis 100.0 100.0 100.0 100.0 100.0
Center 6
Omental cake 100.0 80.0 100.0 87.5 91.6
Peritoneal carcinomatosis 100.0 100.0 100.0 100.0 100.0
Diaphragmatic carcinomatosis 91.6 80.0 100.0 85.7 90.9
Mesenteral retraction 41.6 100.0 100.0 100.0 100.0
Bowel infiltration 91.6 80.0 80.0 83.3 81.8
Stomach infiltration 75.0 n.a. 88.8 n.a. 88.8
Superficial liver metastasis 100.0 87.5 87.5 75.0 83.3
Center 7
Omental cake 83.3 100.0 100.0 100.0 100.0
Peritoneal carcinomatosis 91.6 100.0 85.7 100.0 90.9
Diaphragmatic carcinomatosis 91.6 75.0 100.0 87.5 90.9
Mesenteral retraction 50.0 83.3 n.a. n.a. 83.3
Bowel infiltration 66.6 83.3 100.0 66.7 87.5
Stomach infiltration 91.6 100.0 100.0 n.a. 100.0
Superficial liver metastasis 83.3 100.0 100.0 100.0 100.0
Center 8
Omental cake 100.0 83.3 100.0 87.5 92.3
Peritoneal carcinomatosis 100.0 100.0 100.0 100.0 100.0
Diaphragmatic carcinomatosis 100.0 100.0 66.7 100.0 92.3
Mesenteral retraction 69.2 100.0 80.0 100.0 88.8
Bowel infiltration 84.6 100.0 50.0 100.0 72.7
Stomach infiltration 84.6 100.0 88.9 100.0 90.9
Superficial liver metastasis 92.3 100.0 100.0 100.0 100.0
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SUPPLEMENTARY TABLE
Accuracy of each laparoscopic parameter in each SC (continued)
Variable Assessable, % Specificity, % NPV, % PPV, % Accuracy, %
Center 9
Omental cake 100.0 85.7 100.0 75.0 90.0
Peritoneal carcinomatosis 100.0 77.8 100.0 33.3 80.0
Diaphragmatic carcinomatosis 100.0 85.7 100.0 75.0 90.0
Mesenteral retraction 90.0 85.7 100.0 66.7 88.8
Bowel infiltration 80.0 75.0 75.0 75.0 75.0
Stomach infiltration 100.0 100.0 100.0 100.0 100.0
Superficial liver metastasis 100.0 100.0 88.8 100.0 90.0
Center 10
Omental cake 100.0 100.0 100.0 100.0 100.0
Peritoneal carcinomatosis 100.0 100.0 100.0 100.0 100.0
Diaphragmatic carcinomatosis 100.0 100.0 66.7 100.0 80.0
Mesenteral retraction 90.0 100.0 n.a. n.a. 100.0
Bowel infiltration 100.0 100.0 88.8 100.0 90.0
Stomach infiltration 100.0 100.0 n.a. n.a. 100.0
Superficial liver metastasis 100.0 100.0 88.8 100.0 90.0
n.a., not available; NPV, negative predictive value; PPV, positive predictive value; SC, satellite center.
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